Sandu Pharmaceuticals Limited (BOM:524703)
India
· Delayed Price · Currency is INR 35.00
+1.10 (3.24%)
At close: Mar 10, 2026
Sandu Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 671.5 | 671.92 | 672.81 | 653.49 | 655.01 | 587.55 | Upgrade
|
| Other Revenue | 0 | - | - | - | - | - | Upgrade
|
| Revenue | 671.5 | 671.92 | 672.81 | 653.49 | 655.01 | 587.55 | Upgrade
|
| Revenue Growth (YoY) | -2.28% | -0.13% | 2.96% | -0.23% | 11.48% | 21.28% | Upgrade
|
| Cost of Revenue | 329.6 | 342.36 | 346.4 | 332.83 | 378.31 | 363.39 | Upgrade
|
| Gross Profit | 341.9 | 329.57 | 326.41 | 320.66 | 276.7 | 224.17 | Upgrade
|
| Selling, General & Admin | 180.01 | 181.46 | 177.89 | 169.74 | 138.63 | 118.44 | Upgrade
|
| Other Operating Expenses | 133.12 | 120.46 | 125.57 | 126.05 | 109.33 | 84.14 | Upgrade
|
| Operating Expenses | 319.73 | 308.62 | 309.29 | 300.97 | 253.26 | 208.15 | Upgrade
|
| Operating Income | 22.18 | 20.94 | 17.12 | 19.69 | 23.44 | 16.02 | Upgrade
|
| Interest Expense | -1.06 | -0.97 | -0.54 | -0.72 | -0.74 | -0.65 | Upgrade
|
| Interest & Investment Income | 1.68 | 1.68 | 4.21 | 3.27 | 0.83 | 1.94 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.26 | -0.07 | -0.06 | -0.08 | -0.36 | -0.5 | Upgrade
|
| EBT Excluding Unusual Items | 22.53 | 21.59 | 20.73 | 22.17 | 23.17 | 16.81 | Upgrade
|
| Pretax Income | 22.53 | 21.59 | 20.73 | 22.17 | 23.17 | 16.81 | Upgrade
|
| Income Tax Expense | 2.01 | 6.07 | 6.12 | 6.96 | 7.27 | 5.88 | Upgrade
|
| Net Income | 20.52 | 15.52 | 14.61 | 15.21 | 15.89 | 10.93 | Upgrade
|
| Net Income to Common | 20.52 | 15.52 | 14.61 | 15.21 | 15.89 | 10.93 | Upgrade
|
| Net Income Growth | 13.01% | 6.19% | -3.90% | -4.33% | 45.47% | 51.67% | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 9 | 8 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 9 | 9 | 7 | Upgrade
|
| Shares Change (YoY) | 0.56% | - | 2.42% | 10.93% | 20.08% | - | Upgrade
|
| EPS (Basic) | 2.12 | 1.61 | 1.51 | 1.73 | 1.99 | 1.54 | Upgrade
|
| EPS (Diluted) | 2.11 | 1.60 | 1.51 | 1.61 | 1.87 | 1.54 | Upgrade
|
| EPS Growth | 12.21% | 5.96% | -6.21% | -13.90% | 21.43% | 51.39% | Upgrade
|
| Free Cash Flow | - | 0.1 | -6.65 | -8.48 | 1.08 | 74.63 | Upgrade
|
| Free Cash Flow Per Share | - | 0.01 | -0.69 | -0.90 | 0.13 | 10.54 | Upgrade
|
| Dividend Per Share | - | 0.800 | 0.800 | 0.750 | 0.750 | 0.500 | Upgrade
|
| Dividend Growth | - | - | 6.67% | - | 50.00% | - | Upgrade
|
| Gross Margin | 50.92% | 49.05% | 48.51% | 49.07% | 42.24% | 38.15% | Upgrade
|
| Operating Margin | 3.30% | 3.12% | 2.54% | 3.01% | 3.58% | 2.73% | Upgrade
|
| Profit Margin | 3.06% | 2.31% | 2.17% | 2.33% | 2.43% | 1.86% | Upgrade
|
| Free Cash Flow Margin | - | 0.01% | -0.99% | -1.30% | 0.16% | 12.70% | Upgrade
|
| EBITDA | 26.84 | 25.4 | 21.3 | 23.23 | 26.95 | 19.8 | Upgrade
|
| EBITDA Margin | 4.00% | 3.78% | 3.17% | 3.55% | 4.11% | 3.37% | Upgrade
|
| D&A For EBITDA | 4.67 | 4.46 | 4.18 | 3.54 | 3.51 | 3.77 | Upgrade
|
| EBIT | 22.18 | 20.94 | 17.12 | 19.69 | 23.44 | 16.02 | Upgrade
|
| EBIT Margin | 3.30% | 3.12% | 2.54% | 3.01% | 3.58% | 2.73% | Upgrade
|
| Effective Tax Rate | 8.94% | 28.11% | 29.51% | 31.41% | 31.39% | 35.00% | Upgrade
|
| Revenue as Reported | 672.99 | 673.6 | 677.04 | 656.76 | 655.83 | 589.49 | Upgrade
|
| Advertising Expenses | - | 69.92 | 74.72 | 56.56 | 47.39 | 35.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.